HAEMONETICS CORP HAE
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
7/9
Piotroski F — financial health
2.85
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2026 | $1.3B | $97.3M | $787.6M | $260.4M | $796.3M |
| 2025 | $1.4B | $167.7M | $749.0M | $142.4M | $820.8M |
| 2024 | $1.3B | $117.6M | $691.5M | $143.6M | $960.0M |
| 2023 | $1.2B | $115.4M | $615.1M | $81.7M | $818.0M |
| 2022 | $993.2M | $43.4M | $505.5M | $75.8M | $749.4M |
| 2021 | $870.5M | $79.5M | $397.8M | $71.8M | $731.7M |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.85 (safe)
- Working capital / assets 0.231
- Retained earnings / assets 0.117
- EBIT / assets 0.065
- Equity / liabilities 0.498
Source: SEC EDGAR filings · CIK 0000313143 · as of 2026-03-28. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.